Logo
    Search

    POLITICO's Pulse Check

    POLITICO Pulse Check delivers the latest news in health care with sharp policy analysis and a dose of real-world perspective. Hear what stories POLITICO's deep bench of Health Care policy reporters are watching and their analysis of the critical issues facing regulators, legislators, and practitioners.
    enPOLITICO's Pulse Check600 Episodes

    Episodes (600)

    What Biden's new fair price drug policy means

    What Biden's new fair price drug policy means
    The Biden administration announced Thursday that drug companies receiving research funding from HHS’ emergency response arm, the Administration for Strategic Preparedness and Response, will have to commit to a “fair price” – not more than they charge in other countries. Host Chelsea Cirruzzo talks with POLITICO health care reporter Robert King about the Biden administration's efforts to curb high prescription drug prices.

    Congress’ health reform package: Where does it stand?

    Congress’ health reform package: Where does it stand?
    As Congress pursues landmark health reforms, lawmakers must align House and Senate legislation that includes ensuring transparency from hospitals, insurers and pharmacy benefit managers and reauthorizing a law that would expand treatment for opioid use disorders. Host Megan Messerly talks with POLITICO health care reporter Ben Leonard about the chances of reconciling the chambers’ competing bills.

    Who’s calling the shots on health care policy now?

    Who’s calling the shots on health care policy now?
    Louisiana Republican Mike Johnson's rise to House Speaker and the departure of some key health care policy aides are shifting power on the Hill, giving more sway to the priorities of committee chairs and their senior staffers in the shaping of health care policy in 2024. Host Alice Miranda Ollstein talks with POLITICO health care reporter Megan R. Wilson about the changes.

    Sickle cell gene-editing treatment poised for FDA approval

    Sickle cell gene-editing treatment poised for FDA approval
    The FDA is close to a decision on a landmark one-time gene-editing treatment for patients with sickle cell disease and another blood disorder. Host Kelly Hooper talks with POLITICO health care reporter Lauren Gardner about how the therapy works, its safety profile, who will be eligible for it and the significant challenges around affordability and access.